ReachMD

Dr. Robert Harrington is director of the Duke Clinical Research Institute and a professor of cardiology at the Duke University Medical Center. His research interests include evaluatiing antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issues of risk stratification in the care of patients with acute ischemic coronary syndromes, and trying to better understand and improve upon the methodology of clinical trials. He is the recipient of an NIH GO (Grand Opportunity) grant to investigate incorporate clinical trials into clinical practice registries.  

Dr. Harrington received his undergraduate degree in english from the College of the Holy Cross, Worcester, Massachusetts. He attended Dartmouth Medical School and received his medical degree from Tufts University School of Medicine in 1986. He was an intern, resident and the Chief Medical Resident in internal medicine at the University of Massachusetts Medical Center. He was a fellow in cardiology at Duke University Medical Center, where he received training in interventional cardiology and research training in the Duke Databank for Cardiovascular Diseases. He joined the Duke faculty in the division of cardiology in 1993, where he is currently a professor of medicine and an interventional cardiologist.

He has authored multiple peer-reviewed manuscripts, reviews, book chapters, and editorials. He was one of the senior co-editors for the 8th edition of the American College of Chest Physicians' Consensus Panel on Antithrombotic and Thrombolytic Drugs. He is an associate editor of the American Heart Journal and an editorial board member for the Journal of the American College of Cardiology. He is a fellow of the American College of Cardiology, the American Heart Association, the Society of Cardiovascular Angiography and Intervention, the American College of Chest Physicians and the European Society of Cardiology. He is a member of the board of trustees of the American College of Cardiology.  He recently served as chair of the FDA Cardiovascular and Renal Drugs Advisory Committee.